Searched query = "Peroxisomal disease (except Adrenoleukodystrophy)", "Peroxisomal disease", "Peroxisomal disorder", "Peroxisome biogenesis disorder", "PEX gene disorder", "Zellweger syndrome", "Neonatal adrenoleukodystrophy", "Rhizomelic chondrodysplasia punctata type 1", "RCDP type 1", "RCDP1", "Peroxisomal beta-oxidation enzyme deficiency", "Acyl-CoA oxidase deficiency", "AOX deficiency", "D-Bifunctional protein deficiency", "DBP deficiency", "Sterol carrier protein X deficiency", "SCPx deficiency", "2-methylacyl-CoA racemase deficiency", "Alpha-methylacyl-CoA racemase deficiency", "AMACR deficiency", "Refsum disease", "Plasmalogen biosynthesis enzyme deficiency", "Rhizomelic chondrodysplasia punctata type 2", "RCDP type 2", "RCDP2", "Rhizomelic chondrodysplasia punctata type 3", "RCDP type 3", "RCDP3", "Primary hyperoxaluria type 1", "PH1", "Acatalasemia", "Acatalasia", "Contiguous ABCD1/DXS1357E deletion syndrome", "CADDS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|September 1997||18/10/1999||Study of Bile Acids in Patients With Peroxisomal Disorders||Infantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;Adrenoleukodystrophy||Drug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiol||Children's Hospital Research Foundation University of Cincinnati||Children's Hospital Medical Center, Cincinnati||Terminated||N/A||5 Years||Both||25||N/A||NULL|
|January 1992||6/12/2000||Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid||Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism||Infantile Refsum's Disease;Zellweger Syndrome;Adrenoleukodystrophy;Peroxisomal Disorders;Cholestasis||Drug: Cholic Acids||Travere Therapeutics, Inc.||Children's Hospital Medical Center, Cincinnati||Completed||N/A||N/A||All||85||Phase 3||United States|
|27/10/2010||Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in Zellweger||Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in Zellweger||Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorderThis syndrome encompasses a spectrum of severity in symptomsPreviously the disorder was subdivided into three disorders based on the severity of symptoms; Infantile Refsum disease (IRD) is the mildest form, neonatal adrenoleucodystrofia (NALD) has more severe symptoms and Zellweger syndrome has the most severe clinical symptoms. |
MedDRA version: 12.1;Level: LLT;Classification code 10053706;Term: Zellweger syndrome
MedDRA version: 12.1;Classification code 10038275;Term: Refsum's disease
|Product Name: cholic acid|
Product Code: CA
INN or Proposed INN: Cholic Acid
Other descriptive name: CHOLIC ACID
|Department of Pediatric Gastroenterology, Academic Medical Centre||NULL||NA||Female: yes|